Higgins, R <br/><br/>
To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?  [electronic resource] 

 -  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation  Apr 2005 
 - 392-400 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1053-2498 
<br/><br/><label>Standard No.: </label>10.1016/j.healun.2004.01.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antilymphocyte Serum--therapeutic use<br/>Decision Making<br/>Follow-Up Studies<br/>Graft Rejection--drug therapy<br/>HLA Antigens--immunology<br/>Heart Transplantation<br/>Humans<br/>Immunosuppression Therapy--methods<br/>Immunosuppressive Agents--therapeutic use<br/>Middle Aged<br/>Multivariate Analysis<br/>Muromonab-CD3--therapeutic use<br/>North America--epidemiology<br/>Perioperative Care--methods<br/>Retrospective Studies<br/>Risk Factors<br/>Severity of Illness Index<br/>Survival Rate--trends<br/>T-Lymphocytes--immunology